Show simple item record

dc.contributor.authorAlexander, G.S.
dc.contributor.authorSavla, B.
dc.contributor.authorBerg, L.J.
dc.contributor.authorSun, K.
dc.contributor.authorRemick, J.S.
dc.contributor.authorKowalski, E.S.
dc.contributor.authorChen, S.
dc.contributor.authorLamichhane, N.
dc.contributor.authorRegine, W.F.
dc.contributor.authorMishra, M.V.
dc.date.accessioned2022-04-06T12:11:03Z
dc.date.available2022-04-06T12:11:03Z
dc.date.issued2021-11
dc.identifier.urihttp://hdl.handle.net/10713/18475
dc.description.abstractPD-L1 is often overexpressed in the tumor microenvironment to dampen host immune response and allow tumor proliferation. Radiation works partially through the immune system, but the correlation between PD-L1 expression in primary tumors and oncologic outcomes for metastatic lesions treated with SRS with concurrent immunotherapy (ICI) is unknown. We seek to evaluate the association of PD-L1 expression level of the primary tumor in patients undergoing SRS/fSRT with local control and symptomatic radiation necrosis.en_US
dc.description.urihttps://doi.org/10.1016/j.ijrobp.2021.07.1521en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Radiation Oncology - Biology - Physicsen_US
dc.rightsCopyright © 2021 Published by Elsevier Inc.en_US
dc.rights.urihttps://www.elsevier.com/tdm/userlicense/1.0/
dc.titlePD-L1 Expression Level of Primary Tumor as a Predictor of Local Control and Symptomatic Radiation Necrosis in Patients With Brain Metastases Undergoing SRS/fSRT With Concurrent Immunotherapyen_US
dc.typeAbstracten_US
dc.identifier.doi10.1016/j.ijrobp.2021.07.1521
dc.source.journaltitleInternational Journal of Radiation Oncology*Biology*Physics
dc.source.volume111
dc.source.issue3
dc.source.beginpagee562


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record